SynthesisJournal of neuro-oncology2015
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Synthesis in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Are EGFR monoclonal antibodies associated with clinical benefits in patients with glioma: a systematic review, meta-analysis, and specific analysis on glioblastoma and diffuse intrinsic pontine glioma.Neurosurgical review · 2025Pooled it
- Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review.Journal of neuro-oncology · 2018Pooled it
- Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma.African health sciences · 2025Article
- Fotemustine in recurrent high‑grade glioma: MRI neuro‑radiological findings.Oncology letters · 2024Article
- Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes.Current oncology (Toronto, Ont.) · 2024Review
- The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.Frontiers in immunology · 2024Review
- Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.Cancer management and research · 2024Article
- Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis.Experimental and therapeutic medicine · 2023Article
- The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.Frontiers in oncology · 2023Article
- GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.CNS neuroscience & therapeutics · 2022Article
- Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis.Cell death & disease · 2021Article
- High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- A potentially effective drug for patients with recurrent glioma: sermorelin.Annals of translational medicine · 2021Article
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.Frontiers in oncology · 2021Article
- Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms.Molecules (Basel, Switzerland) · 2019Review
- Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study.OncoTargets and therapy · 2019Article
- Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line.Oncology research · 2018Article
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.Neurologia medico-chirurgica · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG). The PubMed and EMBASE databases were searched from the earliest records to February 2015, which identified 33 studies with 1760 participants that met the inclusion criteria. The standard schedule and three most common dose-dense regimens of TMZ therapy for recurrent HGG were included in this meta-analysis. The schedule of 7 days on/7 days off for the treatment of grade IV gliomas was significantly superior to the standard regimen with respect to progression-free survival at 6 months (34.8 %; 95 % confidence interval (CI) 27.0-43.4 %) and 12 months (15.5 %; 95 % CI 10.7-21.8 %). For grade III gliomas, this regimen conveyed a significantly greater overall survival (OS) rate at 12 months (79.0 %; 95 % CI 56.2-91.7 %), as compared to the standard schedule. Also, the 21 days on/7 days off regimen had significantly longer OS rates at 6 months (73.6 %; 95 % CI 63.4-81.8 %) and 12 months (40.6 %; 95 % CI 32.6-48.6 %) than the standard regimen for grade IV gliomas. In addition, the standard schedule showed a significantly higher clinical benefit rate than the 7 days on/7 days off and 21 days on/7 days off regimens. However, the grade 3-4 toxicity rate of lymphopenia of the standard schedule was 76.5 % (95 % CI 45.5-92.7 %), which was the highest among the four regimens. Recurrent HGG patients receiving personalized treatment should be closely followed up, especially those with concurrent hematological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.